LEGATO is an EU-funded phase III randomised pragmatic clinical trial on Recurrent Glioblastoma

LEGATO project

The LEGATO project is proposing an investigator-initiated phase III randomised pragmatic clinical trial.

Recurrent glioblastoma

Recurrent glioblastoma is an invariably fatal refractory cancer with dismal prognosis. Patients suffer from low quality of life and very burdensome symptoms.


Cost-effectiveness analysis will be performed to investigate the economic value of adding radiation treatment to lomustine chemotherapy.

About Legato

We provide renewed optimism to patients with recurrent glioblastoma through the groundbreaking LEGATO project

We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, radiation oncologists, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment.”

Quality of life

Diagnosis and treatment


Cancer mission

In the media

Coming soon.

Our Blog

Lates News & Articles